OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia
Bharati Shriyan, Parsshava Mehta, Anand Patil, et al.
European Journal of Clinical Pharmacology (2022) Vol. 78, Iss. 8, pp. 1321-1330
Closed Access | Times Cited: 6
Bharati Shriyan, Parsshava Mehta, Anand Patil, et al.
European Journal of Clinical Pharmacology (2022) Vol. 78, Iss. 8, pp. 1321-1330
Closed Access | Times Cited: 6
Showing 6 citing articles:
Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation
Shiyu He, Qian-hang Shao, Jinxia Zhao, et al.
Cancer Chemotherapy and Pharmacology (2023) Vol. 92, Iss. 5, pp. 399-410
Closed Access | Times Cited: 5
Shiyu He, Qian-hang Shao, Jinxia Zhao, et al.
Cancer Chemotherapy and Pharmacology (2023) Vol. 92, Iss. 5, pp. 399-410
Closed Access | Times Cited: 5
Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients
Jaya Shree Dilli Batcha, Vikram Gota, Saikumar Matcha, et al.
Cancer Chemotherapy and Pharmacology (2024) Vol. 94, Iss. 1, pp. 35-44
Open Access | Times Cited: 1
Jaya Shree Dilli Batcha, Vikram Gota, Saikumar Matcha, et al.
Cancer Chemotherapy and Pharmacology (2024) Vol. 94, Iss. 1, pp. 35-44
Open Access | Times Cited: 1
Understanding the impact of ABCG2 polymorphisms on drug pharmacokinetics: focus on rosuvastatin and allopurinol
Anne Kasten, Ingolf Cascorbi
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 6, pp. 519-528
Closed Access | Times Cited: 1
Anne Kasten, Ingolf Cascorbi
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 6, pp. 519-528
Closed Access | Times Cited: 1
Personalized Dose of Adjuvant Imatinib in Patients with Gastrointestinal Stromal Tumors: Results from a Population Pharmacokinetic Analysis
Xuehui Jiang, Qun Fu, Jing Yan, et al.
Drug Design Development and Therapy (2023) Vol. Volume 17, pp. 809-820
Open Access | Times Cited: 3
Xuehui Jiang, Qun Fu, Jing Yan, et al.
Drug Design Development and Therapy (2023) Vol. Volume 17, pp. 809-820
Open Access | Times Cited: 3
Therapeutic Drug Monitoring And Pharmacogenetics to Tune Imatinib Exposure In Gastrointestinal Stromal Tumor Patients: Hurdles and Perspectives for Clinical Implementation
Sara Gagno, Chiara Dalle Fratte, Bianca Posocco, et al.
Pharmacogenomics (2009) Vol. 24, Iss. 18, pp. 895-900
Open Access | Times Cited: 3
Sara Gagno, Chiara Dalle Fratte, Bianca Posocco, et al.
Pharmacogenomics (2009) Vol. 24, Iss. 18, pp. 895-900
Open Access | Times Cited: 3
Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia Patients
Heriberto Bruzzoni‐Giovanelli, Habib Zouali, Mourad Sahbatou, et al.
Pharmaceutics (2024) Vol. 16, Iss. 6, pp. 834-834
Open Access
Heriberto Bruzzoni‐Giovanelli, Habib Zouali, Mourad Sahbatou, et al.
Pharmaceutics (2024) Vol. 16, Iss. 6, pp. 834-834
Open Access
